{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:31:29Z","timestamp":1794274289168,"version":"4.9.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As part of a phase 1 or 2 study, this single-arm expansion cohort established the efficacy and safety of mosunetuzumab monotherapy in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) (received \u22652 previous lines of therapy). Intravenous mosunetuzumab was administered with cycle (C) 1 step-up dosing for cytokine release syndrome (CRS) mitigation: C1\u00a0day (D) 1: 1\u00a0mg; C1D8 2\u00a0mg; C1D15 and C2D1: 60\u00a0mg; C3\u00a0+ D1: 30\u00a0mg. Hospitalization was not mandatory. Patients with complete response (CR) completed treatment after C8; those with partial response or stable disease continued treatment for a total of 17 cycles. The primary end point was CR rate (best response), assessed against a historical control CR rate (20%) by independent review facility. Eighty-eight patients (73.9% de novo DLBCL; 26.1% transformed follicular lymphoma) were enrolled; all had received previous anthracycline and anti-CD20 therapy. Overall response and CR rates were 42.0% (95% confidence interval [CI], 31.6-53.1) and 23.9% (95%\u00a0CI, 15.4-34.1), respectively; CR rate did not reach statistical significance vs the historical control (P\u00a0= .36). Median time to first response was 1.4\u00a0months. Median progression-free survival was 3.2\u00a0months (95%\u00a0CI, 2.2-5.3). The CR rate in 26 patients who received previous chimeric antigen receptor T-cell (CAR-T) therapy was 12%. CRS was one of the most common adverse events (26.1% of patients); predominantly grade 1 to 2 and primarily in C1. Four patients (4.5%) discontinued mosunetuzumab owing to adverse events. Mosunetuzumab demonstrated notable efficacy and a manageable safety profile in patients with R\/R DLBCL, including those previously treated with CAR-Ts. This trial was registered at www.clinicaltrials.gov as #NCT02500407.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009260","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T12:35:19Z","timestamp":1681734919000},"page":"4926-4935","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":110,"title":["Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"7","author":[{"given":"Nancy L.","family":"Bartlett","sequence":"first","affiliation":[{"name":"1Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[{"name":"2Division of Haematology, Jewish General Hospital, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratyush","family":"Giri","sequence":"additional","affiliation":[{"name":"3Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Linear Clinical Research, University of Western Australia and Sir Charles Gairdner Hospital, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew","family":"Matasar","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-0682","authenticated-orcid":false,"given":"Gareth P.","family":"Gregory","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Monash Health and School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[{"name":"8Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"9Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Fay","sequence":"additional","affiliation":[{"name":"10Department of Haematology, St. Vincent\u2019s Hospital and Royal North Shore Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":false,"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"11Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Panizo","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-290X","authenticated-orcid":false,"given":"Ian","family":"Flinn","sequence":"additional","affiliation":[{"name":"13Lymphoma Research, Sarah Cannon Research Institute\/Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5959-5203","authenticated-orcid":false,"given":"Anna","family":"Johnston","sequence":"additional","affiliation":[{"name":"14Department of Haematology, University of Tasmania and Royal Hobart Hospital, Hobart, TAS, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[{"name":"15Department of Hematology, University Hospital Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"16Department of Medical Oncology, BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada"},{"name":"17Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wei","sequence":"additional","affiliation":[{"name":"18Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Yin","sequence":"additional","affiliation":[{"name":"18Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"To","sequence":"additional","affiliation":[{"name":"18Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9590-3450","authenticated-orcid":false,"given":"Chi-Chung","family":"Li","sequence":"additional","affiliation":[{"name":"18Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Huang","sequence":"additional","affiliation":[{"name":"19Hoffmann-La Roche Ltd, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Kwan","sequence":"additional","affiliation":[{"name":"18Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elicia","family":"Penuel","sequence":"additional","affiliation":[{"name":"18Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[{"name":"20Deaprtment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"issue":"4","key":"2023091115240001700_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023091115240001700_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"suppl 5","key":"2023091115240001700_bib3","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"2023091115240001700_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar-Adaniya","year":"2021","journal-title":"Am J Hematol"},{"key":"2023091115240001700_bib5","doi-asserted-by":"crossref","first-page":"20406207211053120","DOI":"10.1177\/20406207211053120","article-title":"Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma","volume":"12","author":"Rampotas","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"2023091115240001700_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2217\/fon-2020-0522","article-title":"Real-world practice patterns and outcomes in veterans with relapsed\/refractory diffuse large B-cell lymphoma","volume":"17","author":"Chien","year":"2021","journal-title":"Future Oncol"},{"issue":"16","key":"2023091115240001700_bib7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2023091115240001700_bib8","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00277-015-2467-z","article-title":"Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment","volume":"94","author":"Hitz","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"2023091115240001700_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2023091115240001700_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.clml.2020.05.008","article-title":"Real world outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma receiving palliative intent therapies","volume":"20","author":"Ayers","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"2023091115240001700_bib11","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023091115240001700_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2023091115240001700_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"2023091115240001700_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023091115240001700_bib15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"2023091115240001700_bib16","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2023091115240001700_bib17","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"2023091115240001700_bib18","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for B-cell Lymphomas","author":"National Comprehensive Cancer Network","year":"\u00a05.2022"},{"issue":"26","key":"2023091115240001700_bib19","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"287","key":"2023091115240001700_bib20","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3\u00a0T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"2023091115240001700_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023091115240001700_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023091115240001700_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"2023091115240001700_bib24","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1182\/blood-2008-09-177469","article-title":"Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival","volume":"113","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2023091115240001700_bib25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00277-012-1407-4","article-title":"Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL","volume":"91","author":"Suzuki","year":"2012","journal-title":"Ann Hematol"},{"issue":"8","key":"2023091115240001700_bib26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"2023091115240001700_bib27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2023091115240001700_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2021-145872","article-title":"Mosunetuzumab plus polatuzumab vedotin has promising efficacy and a favorable safety profile in patients with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma: updated results from a phase Ib\/II study","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2023091115240001700_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"2023091115240001700_bib30","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"2023091115240001700_bib31","first-page":"775","article-title":"Assessing and management of neurotoxicity after CAR-T therapy in diffuse large B-cell lymphoma","volume":"12","author":"Castaneda-Puglianini","year":"2021","journal-title":"J\u00a0Blood Med"},{"issue":"10306","key":"2023091115240001700_bib32","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2023091115240001700_bib33","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"key":"2023091115240001700_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.HS9.0000843772.15634.49","article-title":"S220: glofitamab induces durable complete remissions and has favorable safety in patients with relapsed\/refractory diffuse large B-Cell lymphoma and \u22652 prior therapies: pivotal phase II expansion results","volume":"6","author":"Dickinson","year":"2022","journal-title":"Hemasphere"},{"key":"2023091115240001700_bib35","article-title":"Primary results of subcutaneous epcoritamab dose expansion in patients with relapsed or refractory large B-cell lymphoma: a phase 2 study","author":"Thieblemont","year":"2022","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2023091115240001700_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136255","article-title":"Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"136","author":"Olszewski","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2023091115240001700_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-136295","article-title":"Mosunetuzumab, a novel CD20\/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2023091115240001700_bib38","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"2023091115240001700_bib39","unstructured":"Cheah\n              CY\n            , BartlettNL, AssoulineS, . Mosunetuzumab retreatment is effective and well-tolerated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. EHA 2022 Congress. Abstract P1124. Accessed 18 January 2023. https:\/\/library.ehaweb.org\/eha\/2022\/eha2022-congress\/357985\/chan.yoon.cheah.mosunetuzumab.retreatment.is.effective.and.well-tolerated.in.html?f=listing57983D35798357982Abrowseby57983D35798857982Asortby57983D35798157982Amedia57983D357981."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4926\/2077162\/blooda_adv-2022-009260-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4926\/2077162\/blooda_adv-2022-009260-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:24:46Z","timestamp":1694431486000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/4926\/495381\/Mosunetuzumab-monotherapy-is-active-and-tolerable"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":39,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009260","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}